Get the Stockscreener App
79.77
0.62%
0.49
After Hours:
78.57
-1.20
-1.50%
Belite Bio Inc Adr stock is traded at $79.77, with a volume of 29,743.
It is up +0.62% in the last 24 hours and up +14.81% over the past month.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
See More
Previous Close:
$79.28
Open:
$80
24h Volume:
29,743
Relative Volume:
0.55
Market Cap:
$2.54B
Revenue:
-
Net Income/Loss:
$-32.61M
P/E Ratio:
-67.94
EPS:
-1.1742
Net Cash Flow:
-
1W Performance:
+2.14%
1M Performance:
+14.81%
6M Performance:
+40.94%
1Y Performance:
+44.20%
1-Day Range:
$78.81
$80.19
1-Week Range:
$76.23
$80.19
52-Week Range:
$49.00
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
79.77 | 2.60B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
Belite Bio Inc Adr Stock (BLTE) Latest News
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Belite Bio (NASDAQ:BLTE) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
What MACD signals say about Belite Bio Inc Depositary Receipt2025 Top Gainers & Real-Time Market Trend Scan - newser.com
GAMMA Investing LLC Trims Stock Holdings in Belite Bio, Inc. Sponsored ADR $BLTE - Defense World
3 Lesser-Known Healthcare Names With Major Upside in Store - Investing.com
Volume spikes in Belite Bio Inc Depositary Receipt stock – what they mean2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Juvenile Macular Degeneration Pipeline 2025: Innovative Clinical Developments by 80+ Global Leaders – DelveInsight | Highlighting Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen - Barchart.com
Belite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeHere's Why - MarketBeat
Belite Bio (NASDAQ:BLTE) Upgraded at Wall Street Zen - MarketBeat
Belite Bio (NASDAQ:BLTE) Upgraded by Zacks Research to "Hold" Rating - MarketBeat
Analysts Set Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) PT at $96.00 - MarketBeat
HC Wainwright Has Positive Outlook of Belite Bio Q3 Earnings - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives $96.00 Average Target Price from Analysts - Defense World
HC Wainwright Has Lowered Expectations for Belite Bio (NASDAQ:BLTE) Stock Price - MarketBeat
Oculis Holding (OCS) Gets a Buy from H.C. Wainwright - The Globe and Mail
What is HC Wainwright’s Estimate for Belite Bio Q3 Earnings? - Defense World
Belite Bio concludes phase 3 DRAGON study for Stargardt disease - Modern Retina
VolitionRX (VNRX) Gets a Hold from Benchmark Co. - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Given New $98.00 Price Target at HC Wainwright - Defense World
Belite Bio Shares Climb Amid Clinical Progress - TipRanks
Belite Bio stock price target lowered to $98 at H.C. Wainwright on share count - Investing.com
Promising Outlook for Belite Bio, Inc. Amidst Phase 3 Success and Strong Financial Position - TipRanks
Belite Bio (NASDAQ:BLTE) Shares Gap UpHere's Why - MarketBeat
Using RSI to spot recovery in Belite Bio Inc Depositary ReceiptJuly 2025 Patterns & Consistent Profit Alerts - Newser
Will earnings trigger a reversal in Belite Bio Inc Depositary ReceiptEarnings Growth Summary & Low Drawdown Investment Ideas - Newser
Belite Bio completes last subject visit in phase 3 Stargardt trial - Investing.com
First-Ever Phase 3 Trial for Stargardt Disease: Belite Bio's Tinlarebant Could Be Breakthrough Treatment - Stock Titan
How to build a dashboard for Belite Bio Inc Depositary Receipt stock2025 Price Targets & Community Consensus Picks - Newser
Alyeska Investment Group L.P. Makes New Investment in Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat
Belite Bio, Inc. ADR (BLTE) Gets a Buy from Benchmark Co. - The Globe and Mail
Belite Bio Secures $125 Million in PIPE Financing with Potential for More - MSN
Benchmark reiterates Buy rating on Belite Bio stock after $275 million PIPE - Investing.com
Resilient Performance and Strategic Growth Drive Buy Rating for Harvard Bioscience Amid Market Challenges - TipRanks
Belite Bio raises $125 million in private placement for eye disease drugs By Investing.com - Investing.com South Africa
Belite Bio raises $125 million in private placement for eye disease drugs - Investing.com
$275M Biotech Deal: Belite Bio Lands Major Financing for Eye Disease Treatments from Top Healthcare Funds - Stock Titan
Belite Bio (NASDAQ:BLTE) Stock Price Down 2.3%Here's Why - MarketBeat
Belite Bio (NASDAQ:BLTE) Shares Down 2.3% – Here’s What Happened - Defense World
Can Belite Bio Inc Depositary Receipt maintain its current growth rateMarket Movers & Safe Entry Point Identification - خودرو بانک
Developing predictive dashboards with Belite Bio Inc Depositary Receipt data2025 Big Picture & Long-Term Growth Stock Strategies - Newser
Does Belite Bio Inc Depositary Receipt fit your quant trading model2025 Technical Patterns & Long-Term Safe Investment Plans - Newser
Belite Bio’s Earnings Call: Progress Amid Challenges - MSN
Is Belite Bio Inc Depositary Receipt showing signs of accumulationQuarterly Earnings Report & Entry and Exit Point Strategies - Newser
Clinical-Stage Biotech Belite Bio Secures Speaking Slots at Three Premier Healthcare Conferences - Stock Titan
Multi factor analysis applied to Belite Bio Inc Depositary ReceiptQuarterly Performance Summary & AI Driven Price Forecasts - Newser
Is Belite Bio Inc Depositary Receipt stock bottoming out2025 Price Momentum & Fast Exit Strategy with Risk Control - Newser
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):